178 related articles for article (PubMed ID: 28153838)
1. Myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis with co-mutated JAK2 and SF3B1.
Reinig EF; He R
Blood; 2017 Feb; 129(5):656. PubMed ID: 28153838
[No Abstract] [Full Text] [Related]
2. JAK2 exon 12 mutation in myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis: Not an exclusive mutation to polycythaemia vera.
Inano T; Araki M; Morishita S; Imai M; Yasuda H; Nitta H; Ito M; Edahiro Y; Ochiai T; Misawa K; Fukuda Y; Ohsaka A; Komatsu N
Br J Haematol; 2019 Oct; 187(1):e27-e31. PubMed ID: 31418453
[No Abstract] [Full Text] [Related]
3. Myelodysplastic/myeloproliferative neoplasm with ring sideroblasts, thrombocytosis, and mutated JAK2/SF3B1 without anemia.
Neumann NM; Wen KW
Blood; 2022 Jan; 139(3):466. PubMed ID: 35050328
[No Abstract] [Full Text] [Related]
4. JAK2/CALR/SF3B1 triple-mutated myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis evolving to myelofibrosis and SF3B1 single-mutated acute myeloid leukemia: Evidence of a pre-JAK2 clone.
Yasuda H; Morishita S; Mori Y; Tsukune Y; Inano T; Harada S; Komatsu N
Leuk Res; 2021 Jan; 100():106496. PubMed ID: 33373831
[No Abstract] [Full Text] [Related]
5. Revisiting diagnostic criteria for myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis: Borderline cases without anemia exist.
Li P; Shahmarvand N; Lynch D; Gotlib JR; Merker JD; Zehnder JL; George TI; Ohgami RS
Int J Lab Hematol; 2019 Jun; 41(3):345-352. PubMed ID: 30811101
[TBL] [Abstract][Full Text] [Related]
6. High frequencies of SF3B1 and JAK2 mutations in refractory anemia with ring sideroblasts associated with marked thrombocytosis strengthen the assignment to the category of myelodysplastic/myeloproliferative neoplasms.
Jeromin S; Haferlach T; Grossmann V; Alpermann T; Kowarsch A; Haferlach C; Kern W; Schnittger S
Haematologica; 2013 Feb; 98(2):e15-7. PubMed ID: 22929973
[No Abstract] [Full Text] [Related]
7. Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis with Cooccurrent SF3B1 and MPL Gene Mutations: A Case Report and Brief Review of the Literature.
Park CH; Yun JW; Kim HY; Lee KO; Kim SH; Kim HJ
Lab Med; 2020 May; 51(3):315-319. PubMed ID: 31858134
[TBL] [Abstract][Full Text] [Related]
8. Splicing factor mutations in MDS RARS and MDS/MPN-RS-T.
Yoshimi A; Abdel-Wahab O
Int J Hematol; 2017 Jun; 105(6):720-731. PubMed ID: 28466384
[TBL] [Abstract][Full Text] [Related]
9. Clinical characteristics of Japanese patients with myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis.
Edahiro Y; Ochiai T; Hashimoto Y; Morishita S; Shirane S; Inano T; Furuya C; Koike M; Noguchi M; Usuki K; Shiratsuchi M; Nakajima K; Ohtsuka E; Tanaka H; Kawata E; Nakamae M; Ueda Y; Aota Y; Sugita Y; Ohara S; Yamasaki S; Asagoe K; Yoshida S; Yamanouchi J; Suzuki S; Kondo T; Kanisawa Y; Toyama K; Omura H; Mizuchi D; Sakamaki S; Ando M; Komatsu N
Int J Hematol; 2023 Jul; 118(1):47-53. PubMed ID: 37058247
[TBL] [Abstract][Full Text] [Related]
10. Myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis: Ringing in a new future.
Nathan DI; Feld J; El Jamal SM; Mascarenhas J; Tremblay D
Leuk Res; 2022 Apr; 115():106820. PubMed ID: 35279478
[TBL] [Abstract][Full Text] [Related]
11. Refractory anemia with ring sideroblasts.
Malcovati L; Cazzola M
Best Pract Res Clin Haematol; 2013 Dec; 26(4):377-85. PubMed ID: 24507814
[TBL] [Abstract][Full Text] [Related]
12. Chronic myeloid neoplasms harboring concomitant mutations in myeloproliferative neoplasm driver genes (JAK2/MPL/CALR) and SF3B1.
Ok CY; Trowell KT; Parker KG; Moser K; Weinberg OK; Rogers HJ; Reichard KK; George TI; Hsi ED; Bueso-Ramos CE; Tam W; Orazi A; Bagg A; Arber DA; Hasserjian RP; Wang SA
Mod Pathol; 2021 Jan; 34(1):20-31. PubMed ID: 32694616
[TBL] [Abstract][Full Text] [Related]
13. Clinical, genomic, and transcriptomic differences between myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T) and myelodysplastic syndrome with ring sideroblasts (MDS-RS).
Montalban-Bravo G; Kanagal-Shamanna R; Darbaniyan F; Siddiqui MT; Sasaki K; Wei Y; Yang H; Chien KS; Naqvi K; Jabbour E; Kadia TM; Daver N; DiNardo C; Ravandi F; Pemmaraju N; Bose P; Verstovsek S; Pierce S; Bueso-Ramos C; Patel K; Do KA; Kantarjian H; Garcia-Manero G
Am J Hematol; 2021 Jul; 96(7):E246-E249. PubMed ID: 33811786
[No Abstract] [Full Text] [Related]
14. MDS/MPN-RS-T justified inclusion as a unique disease entity?
Montalban-Bravo G; Garcia-Manero G
Best Pract Res Clin Haematol; 2020 Jun; 33(2):101147. PubMed ID: 32460979
[TBL] [Abstract][Full Text] [Related]
15. Myelodysplastic syndromes with ring sideroblasts (MDS-RS) and MDS/myeloproliferative neoplasm with RS and thrombocytosis (MDS/MPN-RS-T) - "2021 update on diagnosis, risk-stratification, and management".
Patnaik MM; Tefferi A
Am J Hematol; 2021 Mar; 96(3):379-394. PubMed ID: 33428785
[TBL] [Abstract][Full Text] [Related]
16. Concurrent
Ye MT; Wang Y; Wang SA; Pemmaraju N; Daver N; Verstovsek S; Zhang Y; Zuo Z; Medeiros LJ; You MJ
Leuk Lymphoma; 2020 Apr; 61(4):963-966. PubMed ID: 31750750
[No Abstract] [Full Text] [Related]
17. [A case report of RARS-T with SF3B1 and CALR mutations].
Ge H; Zhou Z; Chu H
Zhonghua Xue Ye Xue Za Zhi; 2016 Apr; 37(4):347. PubMed ID: 27094003
[No Abstract] [Full Text] [Related]
18. Age, JAK2(V617F) and SF3B1 mutations are the main predicting factors for survival in refractory anaemia with ring sideroblasts and marked thrombocytosis.
Broséus J; Alpermann T; Wulfert M; Florensa Brichs L; Jeromin S; Lippert E; Rozman M; Lifermann F; Grossmann V; Haferlach T; Germing U; Luño E; Girodon F; Schnittger S;
Leukemia; 2013 Sep; 27(9):1826-31. PubMed ID: 23594705
[TBL] [Abstract][Full Text] [Related]
19. Predictors of survival in refractory anemia with ring sideroblasts and thrombocytosis (RARS-T) and the role of next-generation sequencing.
Patnaik MM; Lasho TL; Finke CM; Hanson CA; King RL; Ketterling RP; Gangat N; Tefferi A
Am J Hematol; 2016 May; 91(5):492-8. PubMed ID: 26874914
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathological and molecular features of SF3B1-mutated myeloproliferative neoplasms.
Boiocchi L; Hasserjian RP; Pozdnyakova O; Wong WJ; Lennerz JK; Le LP; Dias-Santagata D; Iafrate AJ; Hobbs GS; Nardi V
Hum Pathol; 2019 Apr; 86():1-11. PubMed ID: 30594750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]